WaferGen Bio-systems (WGBS) Misses Q2 EPS by 2c, Lowers FY Revenue Guidance

WaferGen Bio-systems (NASDAQ: WGBS) reported Q2 EPS of ($0.67), $0.02 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.1 million.

2015 Guidance

Based on current sales trends and expectations, WaferGen is revising full-year 2015 revenue guidance to $7.5 million - $7.8 million, down from $8.0 million - $8.5 million. This guidance excludes revenue from our single cell products, currently being developed. At present, we cannot predict with any degree of certainty the timing of revenue for the single cell products we intend to commercialize

For earnings history and earnings-related data on WaferGen Bio-systems (WGBS) click here.

You May Also Be Interested In

• Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
• Docusign shares soar on strong Q2 print, upbeat ARR guidance
• Smith & Wesson Brands (SWBI) Tops Q1 EPS by 13c